Home › Acute Biphenotypic Leukemia › North Carolina
Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia sa North Carolina
11 pag-aaral para sa Acute Biphenotypic Leukemia ang naghahanap ng mga kalahok sa mga site sa North Carolina.
Mga Lungsod sa North Carolina
- Durham8 pag-aaral
- Charlotte6 pag-aaral
- Greenville4 pag-aaral
- Asheville3 pag-aaral
- Winston-Salem3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- at 2 pa
Nagre-recruitPhase 2
365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Duke University Medical Center, Durham
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- at 4 pa
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- at 4 pa
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Nagre-recruitPhase 4
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT06289673Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- at 4 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825A Study of Revumenib and Mezigdomide in People With Leukemia
- University of North Carolina (Data Collection Only), Chapel Hill
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT07356154Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.